Suppr超能文献

[老年缺血性心脏病的治疗。地尔硫䓬、维拉帕米和加洛帕米的比较]

[Treatment of ischemic heart disease in the elderly. Comparison of diltiazem, verapamil and gallopamil].

作者信息

Simonelli P, Papa A, Macciocchi B, Auriemma F, Vetrano A, Scaletta Romeo di Santillo M, Ceriello A

机构信息

IRCCS Sanatrix, Pozzilli Isernia.

出版信息

Minerva Cardioangiol. 1993 May;41(5):193-204.

PMID:8355859
Abstract

The medical therapy of myocardial ischemia in elderly patients has not been well evaluated. We studied the age-related changes in 127 patients with proved coronary artery disease and stable effort angina the efficacy and the safety of diltiazem 120 mg tid, verapamil 120 mg tid and gallopamil 50 mg tid a medium term parallel, double blind cross-over placebo controlled study. All patients have been clinically and ergometrically evaluated. In middle-age patients diltiazem, verapamil and gallopamil induced a significant increasing of exercise duration and time to onset ST segment depression > or = 1 mm. In the elderly patients both verapamil and diltiazem as increased the exercise duration and ischemic threshold, while the diltiazem did not increased the exercise duration even if the time of onset ST segment depression > or = 1 mm is increased. At peak exercise the ST segment depression have been reduced both in middle-age and elderly patients after active drugs. Weekly angina and DNT consumption have been significantly reduced after diltiazem, verapamil and gallopamil in middle-age and elderly patients. Side effects have not been relevant even if gallopamil as a lower frequency of them in comparison to diltiazem and verapamil. No patients stopped the treatment because major side effects. Our experience suggests that diltiazem, verapamil and gallopamil have a similar efficacy and rare well tolerated. The choice of one instead of another must be suggested on the basis of side effects developing.

摘要

老年患者心肌缺血的药物治疗尚未得到充分评估。我们在127例确诊为冠状动脉疾病且患有稳定劳力性心绞痛的患者中,进行了一项中期平行、双盲交叉、安慰剂对照研究,研究了地尔硫䓬120毫克每日三次、维拉帕米120毫克每日三次和加洛帕米50毫克每日三次与年龄相关的变化、疗效及安全性。所有患者均接受了临床和运动测试评估。在中年患者中,地尔硫䓬、维拉帕米和加洛帕米均显著增加了运动持续时间以及ST段压低≥1毫米的发作时间。在老年患者中,维拉帕米和地尔硫䓬均增加了运动持续时间和缺血阈值,而地尔硫䓬虽未增加运动持续时间,但增加了ST段压低≥1毫米的发作时间。在运动峰值时,使用活性药物后中年和老年患者的ST段压低均有所减轻。地尔硫䓬、维拉帕米和加洛帕米治疗后,中年和老年患者每周心绞痛发作次数和硝酸酯类药物使用量均显著减少。即使加洛帕米的副作用发生率低于地尔硫䓬和维拉帕米,但副作用均不明显。没有患者因严重副作用而停止治疗。我们的经验表明,地尔硫䓬、维拉帕米和加洛帕米具有相似的疗效,且耐受性良好。应根据副作用的发生情况来选择使用其中一种药物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验